Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome . (22nd April 2022)

• Record Type: Journal Article
• Authors: Gaylis, Norman B; Ritter, Angela; Kelly, Scott A; Pourhassan, Nader Z; Tiwary, Meenakshi; Sacha, Jonah B; Hansen, Scott G; Recknor, Christopher; Yang, Otto O
• Is Part Of: Clinical infectious diseases. Volume 75:Number 7(2022)
• Page Start: 1232
• Page End: 1234
• Publication Date: 2022-04-22
• Subjects: CCR5 -- leronlimab -- long COVID -- immunosuppression; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac226
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: In an exploratory trial treating "long COVID" with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.